Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Clinision
Montelukast is a potent and selective blocker of the CysLT1 receptor. Accordingly, a recent study has shown that Montelukast can improve symptoms of seasonal allergic rhinitis and asthma in patients with both diseases. For treatment of asthma, Montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form. Asthma and allergic rhinitis have been linked clinically for many years as "one airway one diseases". Patients with allergic asthma and rhinitis are significantly more likely to experience asthma attacks compared to patients with asthma alone. Side effects most commonly reported above placebo included headache, otitis media, upper respiratory infection, and pharyngitis
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>18 years
Signed Informed Consent
Clinical diagnosis of Asthma and Allergic Rhinitis
You may not be if
Previous adverse reaction to Montelukast
History of hyper-eosinophilic disorder other than atopic disease
Female subjects who are pregnant, breast-feeding
Any significant and active pulmonary pathology other than asthma